Business Context and Reporting Period
Xilio Therapeutics, Inc. (XLO) filed this Form 8-K on April 4, 2025, regarding a regulatory notice received from the Nasdaq Stock Market. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Waltham, Massachusetts.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial metric disclosed is the trading price of the Company's common stock, which closed below $1.00 per share for 30 consecutive business days prior to April 4, 2025.
Material Changes
The material event reported is the receipt of a deficiency letter from Nasdaq indicating a failure to satisfy the Minimum Bid Requirement under Listing Rule 5450(a)(1). This deficiency is based on the stock price remaining below $1.00 per share for the last 30 consecutive business days.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has an initial 180-day period (expiring October 1, 2025) to regain compliance. Compliance requires the closing bid price to be at least $1.00 per share for 10 consecutive business days.
- Secondary Options: If the initial period is unsuccessful, the Company may be eligible for an additional 180-day period by transferring its listing to the Nasdaq Capital Market, subject to meeting other listing standards and paying an application fee.
- Delisting Risk: Failure to cure the deficiency during the second period could result in delisting. The Company may appeal such a determination to a Hearings Panel, though success is not assured.
- Management Stance: Management intends to actively monitor the stock price and evaluate options to regain compliance but explicitly states there is no assurance that compliance will be achieved.
Investor Verification Checklist
- Verify the current closing bid price of XLO stock to assess proximity to the $1.00 threshold.
- Monitor the Company's stock price for 10 consecutive business days to determine if the initial compliance window is met.
- Review future filings for any announcements regarding a reverse stock split or other corporate actions intended to increase the share price.
- Check for any subsequent notices from Nasdaq regarding the transfer to the Nasdaq Capital Market or potential delisting determinations.